You've been on Humira for three years. Your disease is well-controlled. Your doctor is happy with your progress. And then you get a letter: your insurance plan is no longer covering Humira, and you need to switch to a biosimilar.
Your doctor isn't sure it's necessary. You're not sure it's safe. And your insurer isn't asking — they're telling.
Here's the framework for pushing back effectively.
The Clinical Guidance on Your Side
The American College of Rheumatology (ACR) and the Spondylitis Association of America have both published guidance stating that mandatory non-medical switching — switching a stable patient from their current biologic purely for cost or formulary reasons — is not recommended.
The key language from ACR guidance is that switching decisions "should be the result of a shared decision-making process between the rheumatologist and the patient" and should not be mandated by insurers or PBMs without clinical rationale.
This guidance doesn't mean biosimilar switching is unsafe — the clinical evidence shows it generally is safe. It means that for a patient who is stable, the decision belongs to the patient and prescriber, not the payer.
This is clinical ammunition for your appeal.
The Legal Framework: What Insurers Are Actually Required to Do
Commercial insurance patients:
Under the ACA, commercial health plans must provide an internal appeals process for any coverage denial or formulary restriction. The key standard is "medical necessity." If your prescriber can document that continuing on Humira is medically necessary — citing your stability, prior treatment history, and ACR guidance — the plan must consider that argument.
Many states have additional protections. California, New York, and several other states have enacted step-therapy reform laws that require insurers to grant exceptions when a patient has been stable on a medication — even if the plan's formulary has changed.
Medicare Advantage patients:
Medicare Advantage plans must cover a 30-day transition supply of any drug you were previously taking, even if it's no longer on their formulary, when you first enroll or when a mid-year formulary change occurs. After the transition period, you have the right to request a coverage determination and appeal a denial.
The Medicare appeals process has strict timelines. A standard appeal decision is required within 7 days; an expedited appeal (if your health is at risk from delay) must be decided within 72 hours.
Medicaid patients:
Medicaid managed care plans must provide a fair hearing process for any coverage denial. If your prescriber documents medical necessity for brand Humira or a specific biosimilar and the plan denies it, you can request a state fair hearing, where an independent reviewer evaluates the clinical evidence.
How to Build a Winning Appeal
Step 1: Get your prescriber's documentation in writing.
Ask your rheumatologist (or gastroenterologist, dermatologist, or other prescribing specialist) for a letter that specifically:
- Documents your current treatment stability and duration
- States that mandatory switching at this time poses risk of disease flare
- Cites ACR guidance on non-mandatory switching
- Uses the word "medically necessary" explicitly
Step 2: File the appeal promptly.
Appeals have deadlines — typically 60 to 180 days from the denial date depending on your plan. Don't wait.
Step 3: Include the clinical literature.
The ACR's position statement on biosimilar switching is publicly available. Including it in your appeal as an attachment strengthens the prescriber's argument. Your prescriber's office may be familiar with doing this — it's worth asking.
Step 4: Request an expedited review if appropriate.
If your disease is not well-controlled, or if you're at a critical point in your treatment (recent flare, recent surgery, new diagnosis), request an expedited appeal. The clinical urgency argument changes the timeline and sometimes the outcome.
Step 5: Request an external review if you lose the internal appeal.
Under federal law, if your internal appeal is denied, you have the right to an independent external review by a third party not affiliated with your insurer. External reviewers overturn internal denials at meaningful rates — particularly when strong prescriber documentation is involved.
If You Lose the Appeal
If all appeals fail and you're required to switch, the transition can be managed safely. See our article on biosimilar switching safety and make sure to enroll in the biosimilar's patient assistance or copay program to ensure cost doesn't become an additional barrier.
ClariMeds can help you identify the right assistance programs if a switch does occur.
This article contains general information about insurance appeals processes and clinical guidelines. It does not constitute medical or legal advice. Consult your prescribing physician and, if necessary, a patient advocate or attorney for situation-specific guidance.